Dewpoint Therapeutics is an American biotechnology company based in Boston, Massachusetts.
Dewpoint participated as an industry partner in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership hosted by the Foundation for the National Institutes of Health.[1]
Name | Position | Notes |
---|---|---|
Kara Carter | Senior Vice President, Discovery Biology | ACTIV Preclinical and TRACE Working Groups |
Investors in Dewpoint Therapeutics include:[2][3][4]
Dewpoint is developing products through partnerships with:[7]
ACTIV. National Institutes of Health (NIH). Retrieved April 1, 2022, from http://archive.today/2022.01.11-042823/https://www.nih.gov/research-training/medical-research-initiatives/activ ↩︎
Series A - Dewpoint Therapeutics - 2019-01-30 - Crunchbase Funding Round Profile. Crunchbase. Retrieved July 3, 2023, from https://www.crunchbase.com/funding_round/dewpoint-therapeutics-series-a--aac46ca0 ↩︎
Series B - Dewpoint Therapeutics - 2020-09-29 - Crunchbase Funding Round Profile. Crunchbase. Retrieved July 3, 2023, from https://www.crunchbase.com/funding_round/dewpoint-therapeutics-series-b--80fadead ↩︎
Bressi, J., & Peterson, S. (2022, February 3). Dewpoint Therapeutics Announces Completion of $150 Million Series C Financing. Dewpoint Therapeutics. https://web.archive.org/web/20230703183902/https://dewpointx.com/dewpoint-therapeutics-announces-completion-of-150-million-series-c-financing/ ↩︎
All Companies. (2022, October 28). General Catalyst. http://archive.today/2022.12.03-033447/https://www.generalcatalyst.com/list ↩︎
Portfolio. SoftBank Vision Fund. Retrieved May 5, 2023, from https://web.archive.org/web/20230505171511/https://visionfund.com/portfolio ↩︎
Pipeline. Dewpoint Therapeutics. Retrieved July 3, 2023, from http://archive.today/2023.07.03-184111/https://dewpointx.com/pipeline/%23partnerships ↩︎